Quality of life in chronic lymphocytic leukemia: A neglected issue

Leukemia and Lymphoma

Volumn 46, Issue 12, 2005, Pages 1709-1714

  Molica, S ^a  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

CLL; Comorbidity; Quality of life; Supportive therapies

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 6; PLACEBO; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE SULFATE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COMORBIDITY; DAILY LIFE ACTIVITY; DISEASE FREE SURVIVAL; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPOGAMMAGLOBULINEMIA; LEUKEMIA REMISSION; LONG TERM CARE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PATIENT CARE; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SOCIAL ADAPTATION; SOCIOECONOMICS;

AGED; ATTITUDE TO HEALTH; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 32144432631     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500244183     Document Type: Review

References (45)

1. Schilsky, R. (2002) End point in clinical trials and the drug approval process Clinical Cancer Research, 8, pp. 935 - 938.
2. Oscier, D and Fegan, C and Hillmen, P and Illidge, T and Johnson, S and Maguire, P and (2004) Guidlines on the diagnosis and management of chronic lymphocytic leukemia British Journal of Haematology, 125, pp. 294 - 317.
3. Muldoon, M and Barger, S and Flory, J and Nanuck, S. (1998) What are quality of life measurements measuring? British Medical Journal, 316, pp. 542 - 545.
4. Mauro, F and Foa, R.(2004) Young patients with chronic lymphocytic leukemia. In Chronic lymphocytic leukaemia. (pp. 401 - 413). Totowa NJ: Humana Press.
5. Byrd, J and Stilgenbauer, S and Flinn, I. (2004) Chronic lymphocytic leukemia Hematology, pp. 163 - 183.
6. Cella, D and Peterman, A and Passik, S and Jacobsen, P and Breitbart, W. (1998) Progress toward guidelines for the management of fatigue Oncology, 11A, pp. 369 - 377.
7. Uggla, C and Aguillar-Santelises, M and Rosen, A and Mellstedt, H and Jondel, M. (1987) Spontaneous production of interleukin-1 activity by chronic lymphocytic leukemia cells Blood, 70, pp. 1851 - 1857.
8. Fayad, A and Keating, M and Reuben, J and O'Brien, S and Lee, B and Lerner, S and Kurzrock, R. (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome Blood, 97, pp. 256 - 263.
9. Foa, R and Massaia, M and Cordone, S and Tos, A and Attisano, C and Guarini, A and (1990) Production of tumor necrosis factor alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of disease Blood, 76, pp. 393 - 400.
10. Ludwig, H and Rai, K and Blade, J and Dammacco, F and Degos, L and Itri, L and (2002) Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: Epoietin treatment recommendations The Hematology Journal, 3, pp. 121 - 130.
11. Littlewood, T and Mandelli, F. (2002) The effects of anemia in hematologic malignancies: More than a symptom Seminars in Oncology, 29, pp. 40 - 44.
12. Harrison, L and Shasha, D and White, C and Ramdeen, B. (2000) Radiotherapy-associated anemia: The scope of the problem The Oncologist, 5, pp. 1 - 7.
13. Rossi, J and Van Hoof, A and De Boeck, K and Johnson, S and Bron, D and Foussard, C and (2004) Efficacy and safety of oral fludarabine phosphate in patients with untreated CLL Journal of Clinical Oncology, 21, pp. 1260 - 1267.
14. Cassileth, B and Lusk, E and Strouse, T and Miller, D and Brown, L and Cross, P and Tenaglia, A. (1984) Psychosocial status in chronic illness New England Journal of Medicine, 311, pp. 506 - 511.
15. Breetvel, I and van Dam, F. (1991) Underreporting by cancer patients: the case of response-shift Society of Science Medicine, 32, pp. 981 - 987.
16. Addington-Hall, J and Kalra, L. (2001) Who should measure quality of life British Medical Journal, 322, pp. 1417 - 1420.
17. Byrd, J and Rai, K and Peterson, B and Appelbaum, F and Morrison, V and Kolitz, J and (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood, 105, pp. 49 - 53.
18. Keating, M and Flinn, I and Jain, V and Binet, J and Hillmen, P and Byrd, J and (2002) Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: Results of a large international study Blood, 99, pp. 3554 - 3561.
19. Levy, V and Porcher, R and Delabarre, F and Leporrier, M and Cazin, B and Chevret, S. (2001) Evaluating treatment strategies in chronic lymphocytic treatment strategies: Use of quality-adjusted survival analysis Journal of Clinical Epidemiology, 54, pp. 747 - 754.
20. Oliva, E and D'Angelo, A and Martino, B and Nobile, F and Dimitrov, B and Perna, A. (2002) More concern about transfusion requirement when evaluating quality of life in anemic patients Journal of Clinical Oncology, 20, pp. 3182 - 3183.
21. Glaspy, J and Bukowski, R and Steinberg, D and Taylor, C and Tchekmedyian, S and Vadhan-Raj, S. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice Journal of Clinical Oncology, 15, pp. 1218 - 1234.
22. Demetri, G and Kris, M and Wade, J and Degos, L and Cella, D. (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study Journal of Clinical Oncology, 16, pp. 3412 - 3425.
23. Abels, R. (1993) Erythropoietin for anaemia in cancer patients European Journal of Cancer, 29((Suppl 2)), pp. 2 - 8.
24. Sabbatini, P. (2000) The relationship between anaemia and quality of life in cancer patients The Oncologist, 5((Suppl 2)), pp. 19 - 23.
25. Littlewood, T and Bajetta, E and Nortier, J and Vercammen, E and Rapoport, B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial Journal of Clinical Oncology, 19, pp. 2865 - 2874.
26. Gabrilove, J and Cleeland, C and Livingston, R and Sarokhan, B and Winer, E and Einhorn, L. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in haemoglobin and quality of life are similar to three-times weekly dosing Journal of Clinical Oncology, 19, pp. 2875 - 2882.
27. Cleeland, C and Demetri, G and Glaspy, J and Cella, D and Russell, K and Cremieux, P and Itri, L. (1999) Identifying haemoglobin level for optimal quality of life: Results of an incremental analysis Proceedings of the American Society of Clinical Oncology, 18, pp. 547.
28. Rose, E and Rai, K and Revicki, D and Brown, R and Reblando, J. (1994) Clinical and health status assessment in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO) Blood, 84((Suppl)), pp. 526a.
29. Pangalis, G and Siakantasis, M and Angelopoulou, M and Vassilakopoulos, T and Dimopoulou, M and Kyrtsonis, M and (2002) Downstaging Rai III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin Haematologica, 87, pp. 570 - 575.
30. Molica, S. (1994) Infections in chronic lymphocytic leukemia: Risk factors, and impact on survival, and treatment Leukemia and Lymphoma, 13, pp. 203 - 214.
31. Bodey, G and Kantoyannis, D and Keating, M.(2004) Infections in patients with chronic lymphocytic leukemia. In Chronic lymphocytic leukaemia. (pp. 343 - 359). Totowa NJ: Humana Press.
32. Molica, S and Musto, P and Chiurazzi, F and Specchia, G and Brugiatelli, M and Cicoria, L and Cooperative Group for the study of Immunoglobulin in Chronic Lymphocytic Leukemia. (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial New England Journal of Medicine, 319, pp. 902 - 907.
33. Molica, S and Musto, P and Chiurazzi, F and (1996) Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study Haematologica, 81, pp. 121 - 126.
34. Weeks, J and Tierney, M and Weinstein, M. (1991) Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia New England Journal of Medicine, 325, pp. 81 - 86.
35. Molica, S and Levato, D. (2001) What is changing in the natural history of chronic lymphocytic leukemia Haematologia, 86, pp. 8 - 12.
36. Charlson, M and Pompei, P and Ales, K and Mackenzie, C. (1987) A new method of classifying prognostic comorbidity in longitudinal studies; development and validation Journal of Chronic Diseases, 40, pp. 373 - 383.
37. Miller, M and Paradis, C and Houck, P and Mazumdar, S and Stack, J and Rifai, A and (1992) Rating chronic medical illness burden in geropsychiatric practice and research: Application of the cumulative illness rating scale Psychiatry Research, 41, pp. 237 - 248.
38. Folstein, M and Folstein, S and McHugh, P. (1975) 'Mini Mental State': A practical method for grading the cognitive status of patiens for the clinician Journal of Psychiatric Research, 12, pp. 189 - 198.
39. Hudson, J.(1998) Nutrition, cancer and aging. In Comprehensive geriatric oncology 2nd ed. (pp. 301 - 306). Amsterdam: Harwood Academic Publishers.
40. Hutner Wirograd, C and Gerety, M and Chung, M. (1991) Screening for frailty: Criteria and predictors of outcomes Journal of the American Geriatric Society, 39, pp. 778 - 784.
41. Cella, D. (1995) Measuring quality of life in palliative care Seminars in Oncology, 22((Suppl 3)), pp. 73 - 81.
42. Cella, D and Tulsky, D and Gray, G and Seration, B and Linn, E and Bonomi, A and (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure Journal of Clinical Oncology, 11, pp. 570 - 579.
43. Aaronson, N and Ahmedzai, S and Bergman, B and Bullinger, M and Cull, A and Duez, N and (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. European Organization for Research and Treatment of Cancer Journal of National Cancer Institute, 85, pp. 365 - 376.
44. Holzner, B and Kemmler, G and Kopp, M and Nguyen-Van-Tam, D and Sperner-Unterweger, B and Greil, R and (2004) Quality of life of patients with chronic lymphocytic leukemia: Results of a longitudinal investigation over one year European Journal of Haematology, 72, pp. 381 - 389.
45. Molica, S and Mauro, F and Callea, V and Gentile, M and Giannarelli, D and Lopez, M and (2005) A gender based score system predicts clinical outcome of patients with early B-cell chronic lymphocytic leukemia Leukemia and Lymphoma, 46, pp. 553 - 560.